Celebrating our 3rd Neuropharmacy MasterClass project winners

We recently completed our 3rd Neuropharmacy MasterClass, where delegates presented the outcomes of their workplace projects, demonstrating how they are translating their learning into practice. It was inspiring to see the dedication and passion delegates brought to improving neurology services and patient care in their local settings.

The winning project, as voted by peers, was presented by Tyler Allen and Emma Stephenson from South Tees Hospitals NHS Foundation Trust. Their work focused on reviewing blood monitoring requirements for disease-modifying therapies (DMTs) in MS, with a goal to streamline processes, reduce duplication and cut unnecessary testing. The team identified opportunities to improve local protocols, aligning them more closely with national guidelines and licensing requirements. By reducing over-monitoring and simplifying workflows, they calculated potential cost savings of approximately £86,470 per year, while also easing the burden on patients and staff. This project highlights the value of continuous review and local optimisation in delivering efficient, patient-centred care. Congratulations to Tyler and Emma!

Two further outstanding projects were recognised as runners-up:

• Evaluation of antibiotic and beta-blocker prescribing in patients with myasthenia gravis – identifying agents with potential to exacerbate symptoms, by Xin Yi Thum, advanced clinical pharmacist at Cambridge University Hospitals NHS Foundation Trust
  
  

• Optimisation of intravenous immunoglobulin doses to reflect national guidance, by Rebecca Murphy, neurology and ophthalmology specialist pharmacist at Guy’s and St Thomas’ NHS Foundation Trust

Congratulations to all delegates who completed the MasterClass. All posters from this and previous cohorts are now available to view in our projects section on our website, a growing library of innovative ideas from neuropharmacists across the country.

In addition to project work, module 2 featured expert-led sessions on Parkinson’s and epilepsy, with a focus on practical case studies. The sessions were well received, offering guidance and tools to support pharmacists in clinical decision-making.

Module 1, held in November last year, covered multiple sclerosis, headache disorders, motor neurone disease and other cross-cutting topics relevant to neuropharmacy practice. Now in its third cohort, the Neuropharmacy MasterClass continues to evolve in line with the changing treatment landscape for neurological conditions. Pharmacists are uniquely placed to support the delivery of neurology services – educating patients, promoting adherence, initiating or advising on treatment plans, and monitoring therapy safety and efficacy. Designed to strengthen the confidence and clinical knowledge of pharmacists, the course aims to maximise their role within the multidisciplinary team.

We are now preparing for the next Neuropharmacy MasterClass, with module 1 planned for 2026 and module 2 expected to follow later in 2026 or in 2027, and we would love to hear from you! If you are interested in attending, or contributing to the future direction of the course, we invite you to register your interest.

This activity has been financially supported by sponsorship from Roche Products Limited and Eisai Limited. The sponsors have had no control over the organisation or educational content of this activity.